<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02847013</url>
  </required_header>
  <id_info>
    <org_study_id>00005133</org_study_id>
    <nct_id>NCT02847013</nct_id>
  </id_info>
  <brief_title>The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section</brief_title>
  <official_title>The Use of Liposomal Bupivacaine in TAP Blocks for Women Undergoing Cesarean Section</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Milton S. Hershey Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Milton S. Hershey Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This present investigation aims to determine whether a transversus abdominous plane(TAP)
      block, utilizing liposomal bupivacaine (Exparel), at the conclusion of a cesarean section
      decreases post-operative pain. The hypothesis is that performance of the TAP block with
      liposomal bupivacaine will decrease post-operative narcotic use.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <primary_completion_date type="Actual">December 17, 2019</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Postoperative narcotic use</measure>
    <time_frame>initial 48 hours postoperatively</time_frame>
    <description>Patient use of standard postoperative narcotics (percocet) will be measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective pain scores using 1-10 VAS system</measure>
    <time_frame>initial 48 hours postoperatively</time_frame>
    <description>Subjective pain scores using 1-10 VAS system will be measured</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Placebo- Tap block w normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>After completion of surgery with closer of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, 20cc of Normal saline will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intervention-Tap block w Liposomal bupivacaine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>After completion of surgery w closure of skin incision a TAP block will be performed. On confirmation of entering the fascial plane, Liposomal bupivacaine 0.33% (10 ml diluted to 20 ml using sterile normal saline) will be injected after negative aspiration. That will complete the intervention. 20 patients will be in this arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TAP block w Liposomal bupivacaine</intervention_name>
    <description>TAP block w Liposomal bupivacaine diluted to 0.66% (20 mLs)</description>
    <arm_group_label>Intervention-Tap block w Liposomal bupivacaine</arm_group_label>
    <other_name>Exparel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TAP block w normal saline</intervention_name>
    <description>TAP block w normal saline -preservative free 0.9% sodium chloride (20mLs)</description>
    <arm_group_label>Placebo- Tap block w normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients &gt;18 years of age

          -  Scheduled cesarean section with or without bilateral tubal ligation

          -  Planned performance of a Pfannenstiel incision

          -  Patients are schedule to have a cesarean section with a member of the Women's Health
             or Maternal and Fetal Medicine Departments at Penn State University Hershey S. Medical
             Center

        Exclusion Criteria:

          -  History of opioid use

          -  History of chronic pain syndrome

          -  Use of general anesthesia during cesarean delivery

          -  Postoperative SICU admission

          -  Postpartum hemorrhage (defined as an Estimated Blood Loss of greater then 1,000mL upon
             completion of the cesarean section)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaimey Pauli, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Milton S. Hershey Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Milton S. Hershey Medical Center</name>
      <address>
        <city>Hershey</city>
        <state>Pennsylvania</state>
        <zip>17033-0850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>July 25, 2016</study_first_submitted>
  <study_first_submitted_qc>July 26, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2016</study_first_posted>
  <last_update_submitted>January 30, 2020</last_update_submitted>
  <last_update_submitted_qc>January 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Milton S. Hershey Medical Center</investigator_affiliation>
    <investigator_full_name>Jaimey M. Pauli, MD</investigator_full_name>
    <investigator_title>OB/GYN Resident</investigator_title>
  </responsible_party>
  <keyword>Postcesarean Section</keyword>
  <keyword>Postoperative</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bupivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

